1. L’instabilité génomique, paramètre limitant l’efficacité des thérapies ciblées en oncologie
- Author
-
Louise-Marie Chevalier, Frédéric Bigot, Alain Morel, Amandine Billaud, Mario Campone, Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Stress Adaptation and Tumor Escape in Breast Cancer (CRCINA-ÉQUIPE 8), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Bernardo, Elizabeth, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
- Subjects
0301 basic medicine ,Genome instability ,Genomic instability ,Cancer Research ,Tumour heterogeneity ,Instabilité génomique ,Personnalisation thérapeutique ,Context (language use) ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Synthetic lethality ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Targeted therapies ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,medicine ,Radiology, Nuclear Medicine and imaging ,Hétérogénéité tumorale ,Tumorigenèse ,business.industry ,Hematology ,General Medicine ,Oncogene Addiction ,Personalized medicine ,3. Good health ,030104 developmental biology ,Oncology ,Thérapies ciblées ,030220 oncology & carcinogenesis ,Cancer cell ,Tumorigenesis ,Cancer research ,Carcinogenesis ,business - Abstract
International audience; Genomic instability is one of the main properties of tumour development, promoting first the acquisition of genetic alterations and thus carcinogenesis. Then, the chronic and anarchic proliferation of cancer cells also supports and contributes to this instability allowing a continuous evolution of the tumour. The accumulation of mutations resulting from that instability contributes to tumour heterogeneity that occurs in a specific environment. The resulting diversity of oncogenic drivers further complicates the characterization of the origin of cancer cells dysfunction and consequently therapeutic decision. However, the consideration of the molecular context in oncology has initiated the development of targeted therapies. Based on the concept of oncogene addiction and synthetic lethality, these new drugs require the characterization and identification of specific tumour biomarkers. Targeted therapies have thus considerably optimized patient management, improving efficiency and quality of life while limiting the side effects observed with conventional chemotherapies. However, despite significant clinical benefits, some major limitations to their administration remain. The study of the current issues related to these new therapeutic molecules is becoming crucial for patient management towards an improvement of personalized medicine.
- Published
- 2020